Filing Details

Accession Number:
0001171843-16-010533
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-07 08:49:27
Reporting Period:
2016-06-06
Filing Date:
2016-06-07
Accepted Time:
2016-06-07 07:49:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1359931 Proteon Therapeutics Inc PRTO Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1622905 Eldridge, George Arthur C/O Proteon Therapeutics
200 West Street
Waltham MA 02451
Sr Vp, Cfo, Treasurer, Sec. No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-06-06 2,750 $5.78 2,750 No 4 P Direct
Common Stock Acquisiton 2016-06-06 425 $5.76 425 No 4 P Indirect As custodian for child's UTMA account
Common Stock Acquisiton 2016-06-06 425 $5.78 425 No 4 P Indirect As custodian for child's UTMA account
Common Stock Acquisiton 2016-06-06 400 $5.78 400 No 4 P Indirect As custodian for child's UTMA account
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Indirect As custodian for child's UTMA account
No 4 P Indirect As custodian for child's UTMA account
No 4 P Indirect As custodian for child's UTMA account
Footnotes
  1. The purchase price of $5.78 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $5.78 to $5.79. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  2. These securities were purchased by the reporting person as custodian for three minor children under the Uniform Transfers to Minors Act. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.